adding an anthracycline to a platinum and fluoropyrimidine doublet (12) .
Paclitaxel, an antimitotic agent that stabilizes microtubules, exhibits in vitro activity against gastric cancer cells (13) . As a single agent, paclitaxel has been shown to achieve response rates ranging from 17% to 28% in patients with gastric cancer (14) (15) (16) . The combination of paclitaxel and oxaliplatin has enhanced anticancer activity against gastric cancer cell lines (17) . With a combination of paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin (POFL) in patients with AGC, Lin et al (18) reported a 57.1% clinical response rate in a phase II study. Against this background we conducted the present study, which analyzed the clinical efficacy and toxicity of combination chemotherapy with POFL in patients affected by AGC.
Patients and methods

Eligibility criteria
One hundred and thirty-eight patients were enrolled in the investigation after being histologically proven to have AGC. The inclusion criteria were as follows: 1) initially diagnosed disease that was locally advanced (unresectable), metastatic, or recurrent; 2) ECOG performance status ≤2; measurable disease by imaging studies; 3) age greater than 18 years; 4) life expectancy >3 months; 5) no prior chemotherapy except for patients who had completed postoperative adjuvant therapy at least 6 months before enrollment; 6) adequate blood, kidney and liver function as defined by an absolute neutrophil count ≥1,000/µL, hemoglobin ≥8.0 /dL, platelets ≥80,000/µL, bilirubin less than 2 mg/dL, estimated creatinine clearance of more than 50 mL/minute or creatinine concentration less than twice the upper limit of normal, and AST, ALT, and alkaline phosphatase less than 2 times the upper limit of normal. Patients were excluded if they 1) were pregnant or lactating, 2) had active bleeding, 3) had received prior chemotherapy in the 3 months before entering the study, or 4) had any history of clinically significant cardiac disease or preexisting peripheral neuropathy or brain metastasis. In addition, patients with any other active carcinoma or history of major neuropsychiatric disease or active infection were excluded. Signed consent forms were obtained from all patients prior to study entry.
Treatment program
The treatment program consisted of paclitaxel at a dose of 135 mg/m 2 given intravenously in 250 mL normal saline as a 3-hour infusion on day 1, followed by oxaliplatin at a dose of 85 mg/m 2 and leucovorin 400 mg/m 2 given in 250 mL of 5% dextrose as an intravenous infusion over 2 hours on day 1, followed by 5-FU 2,400 mg/m 2 given by means of an ambulatory pump as an infusion over a 46-hour period on 3 consecutive days. The cycle was repeated every 2 weeks. To avoid hypersensitivity reactions involving paclitaxel, we gave dexamethasone (20 mg at 1 hour), ranitidine (300 mg at 30 minutes) and diphenylhydramine (50 mg at 30 minutes) before paclitaxel. Management continued for up to 12 cycles until intolerable toxicity or disease progression occurred or treatment withdrawal. The median of 6 cycles of treatment (range, 2-12 cycles) was administered to all patients. Granulocyte colony-stimulating factor (G-CSF) could be administered if needed. The dose could be modified or the cycle length increased if adverse effects developed.
Evaluation of response and toxicity
The pretreatment assessment included relevant medical history, physical examinations, laboratory tests (include complete blood count and biochemical tests), pathology, ECG and radiology. Pretreatment staging was done by computed tomography (CT) scans of the chest, abdomen and pelvis. Radiological evaluation was completed within 2 weeks prior to treatment. During treatment, patients were evaluated by weekly complete blood count. Physical examination, performance status, and serum chemistry were recorded prior to each subsequent cycle. Radiological studies including CT scans were repeated every 4 cycles.
Treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) guidelines. A complete response was defined as the complete disappearance of all measurable lesions for at least 4 weeks without the appearance of new lesions. A partial response was defined as a 30% decrease in the sum of the maximum diameters of measurable lesions from baseline for at least 4 weeks. Stable disease was defined as a lesion decrease of less than 30% or an increase of less than 20%, and progressive disease was defined as a ≥20% increase in the sum of the maximum diameters of measurable lesions from baseline or the appearance of a new lesion.
Patients were considered assessable for response if they had early disease progression or received a minimum of 4 cycles of treatment with at least 1 tumor measurement. If a patient was documented as having a complete response (CR) or a partial response (PR), the response was confirmed at least 4 weeks after the first evident response. At the end of treatment, patients were evaluated for response, observed at 3-month intervals over the first year, and observed for survival thereafter. Time to progression (TTP) was measured from the start of therapy until documented progression, relapse, or death from any cause (patients in remission who received further therapy were censored). OS was measured from the start of therapy until death from any cause. No patient was excluded from the survival analyses. Toxicity was assessed during the period of treatment of each cycle based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0.
Statistical analysis
Descriptive statistics were used to describe the patient population, treatment outcome, and incidence of toxicity. Continuous variables were summarized by displaying descriptive statistics. TTP and OS were estimated from Kaplan-Meier curves, and are presented as median values with 95% confidence intervals (CIs). The statistical data were obtained using the SPSS software package v.16.0. Multivariate analyses using the Cox proportional hazards regression model were performed to assess the impact of the following variables on TTP and OS: sex, age, ECOG performance status, metastatic site, disease status, number of metastases, histological differentiation and location of the primary tumor. Differences were considered significant at p<0.05.
Results
Patient characteristics and clinical data
All patients were evaluated and treated between January 2010 and December 2015 at Fujian Medical Union Hospital and Fujian Provincial Cancer Hospital, and were included in the current analysis with a cutoff date for follow-up of March 2016. The characteristics of the 138 enrolled patients with AGC are listed in Table I . The patients were 98 men and 40 women with a median age of 53 years. The majority of patients (79.7%) had an ECOG performance status of 0 or 1. One hundred and two patients had metastatic disease and 36 patients had recurrent disease after surgery and/or adjuvant chemotherapy. Peritoneum, lymph nodes and liver were the most common sites of metastasis.
Efficacy and survival analysis
Of the total of 138 patients, 12 could not be evaluated for response because of the absence of any measurable lesions or early discontinuation of therapy. The responses of the remaining 126 patients are listed in Table II . The median followup period was 26 months (range, 6-52 months). The overall objective response rate was 56.3% (95% CI, 47.5%-64.9%), with 5 CRs and 66 PRs. The median TTP was 6.7 months (95% CI, 5.8-7.6 months) and the median OS was 12.6 months (95% CI, 11.3-13.9 months) ( Fig. 1) . Two-year OS was 23.0% (95% CI, 15.7%-30.3%) and 3-year OS was 19.8% (95% CI, 12.9%-26.8%). Therefore, the overall disease control rate was 82.5%. Fourteen, 20 and 8 patients were treated with palliative surgery after the third, sixth and ninth cycles, respectively. Pathological stage was ypT3N1M0, ypT4aN1M0, ypT4bN1M0, ypT3N2M0, ypT4aN2M0 and ypT4aN3M0 in 6, 11, 9, 5, 8 and 3 of these patients, respectively, after surgery. Most of the patients had a documented improvement of tumor-related symptoms such as pain and dysphagia, or cessation of tumor-related bleeding; the fecal occult blood test results changed from positive to negative. There was a significant difference in the response rates between patients with ≤2 metastases and patients with ≥3 metastases (p = 0.0001). Table III shows the univariate and multivariate analyses of variables for OS and TTP. Among the clinical factors in the univariate analysis, age, disease status, number of metastases and histological differentiation were found to have significant prognostic impact. Multivariate analysis with a Cox regression model was performed to determine which clinical variables were associated with OS. There were 4 independent prognos- TTP. Metastatic sites including the ovary, peritoneum and lymph nodes were associated with longer TTP than liver, lung and other metastatic sites (bone, pancreas). Salvage treatment was provided for 33 (23.9%) patients who received second-line treatment. Twenty received S-1 as a single agent, and 13 received 5-FU/leucovorin plus irinotecan.
Adverse event analysis
All patients were included in the toxicity evaluation. One hundred and thirty-eight patients were administered a total of 857 cycles, with a median of 6 cycles per patient (range, 2-12 cycles). The median cumulative doses of paclitaxel, oxaliplatin, 5-FU and leucovorin were 2,329 mg/m , respectively. The dose of oxaliplatin and paclitaxel was reduced by 25% for the 23 patients who developed grade 3 peripheral neurotoxicity.
The toxicities observed in the patients are listed in Table IV . The most common grade 3 and 4 hematological toxicities were leukopenia, neutropenia and anemia, and were reported in 37.7%, 50.7% and 17.4% of patients, respectively. Febrile neutropenia was observed in 6 patients and they recovered without complications. The most common grade 3 and 4 nonhematological toxicities were alopecia, fatigue, peripheral neurotoxicity, nausea/vomiting, and stomatitis, and they were reported in 27.5%, 17.4%, 16.7%, 6.5%, and 4.3% of patients, respectively. No treatment-related deaths occurred. 
Discussion
In AGC, systemic chemotherapy is considered the best option for palliative treatment, resulting in better quality of life and survival compared with best supportive care (3). Up to now, treatments for AGC using single agents such as 5-FU or combination regimens based on 5-FU have been documented. These combinations have been reported to be effective. The response rates to first-line or second-line treatment varied from 20% to 64% and the median response durations were 6 to 11 months (4-9). Trastuzumab in combination with chemotherapy can be considered a standard option for patients with HER2-positive AGC or advanced gastroesophageal junction cancer (19) . However, no standard chemotherapy for treating AGC has yet been established. It is thus necessary to develop new regimens, particularly for patients who are inoperable or have recurrences after surgery and who might benefit from palliative chemotherapy. Several new agents have recently become part of thirdgeneration regimens for gastric cancer including a topoisomerase I inhibitor or taxanes. Among these agents, docetaxel has been widely used in AGC and the combination of docetaxel, cisplatin and 5-FU (DCF) showed better efficacy than cisplatin and 5-FU (CF) in terms of tumor response and survival in the V325 trial (20) . The authors reported overall responses rates of 37% and 25% in the DCF group and CF group, respectively, and the duration of TTP and OS was significantly longer in the DCF group, 5.6 months versus 3.7 months and 9.2 months versus 8.6 months, respectively. However, severe hematological toxicities were observed in patients treated with DCF, with 82.3% and 29% grade 3 or 4 neutropenia and febrile neutropenia, respectively (20) . These findings are consistent with other trials involving docetaxel, where 71% of patients had grade 3-4 neutropenia, including 12% with febrile neutropenia (21) . For this reason, the docetaxel combination is difficult to use in the clinic.
Paclitaxel, another taxane, has wide-ranging antitumor activities and a synergistic effect in combination with various other chemotherapeutic agents in gastric cancer. As a single agent, its reported response rates are 17% to 28% (14) (15) (16) . A phase II study compared the combination of paclitaxel plus 5-FU (PF) with docetaxel plus 5-FU (DF) as first-line chemotherapy in patients with AGC. The results showed that PF and DF were similarly effective; however, PF was associated with fewer grade 3 or 4 toxicities than DF (22) . In addition, several phase II-III studies have demonstrated that paclitaxelbased regimens including 5-FU and/or platinum compounds or etoposide give high response rates of 32% to 65% in gastric cancer patients, with a median survival of 6.8-14 months (23) (24) (25) (26) . In a review of phase I and II clinical trials of paclitaxelcontaining chemotherapy for AGC, Sakamoto et al (27) found that weekly administration resulted in less toxicity and better outcomes compared with administration every 3 weeks. However, the convenience for patients and the compliance with the study regimens appeared better with biweekly administration than with weekly or every 3 weeks' administration. A phase II study of biweekly paclitaxel (75 mg/m 2 ) and leucovorin (40 mg/m 2 ) as a 2-hour infusion followed by 5-FU (2,400 mg/m 2 ) as a 46-hour continuous infusion showed that the biweekly paclitaxel-based regimen reduced toxicity and was better tolerable than a weekly or every 3 weeks' paclitaxel-based approach (28) . In our study, combination chemotherapy with paclitaxel (135 mg/m 2 ) using biweekly administration resulted in mostly moderate and manageable toxicities, although some grade 3 and 4 toxicities were seen.
Oxaliplatin, a third-generation platinum compound, has been documented as an effective agent for patients with gastric cancer. The results of recent clinical trials showed that oxaliplatin was at least as effective as cisplatin and was associated with slightly less toxicity and better tolerability (29, 30) . Furthermore, several studies demonstrated that the modified FOLFOX-6 regimen may be effective in patients with AGC, with an overall response rate of 31.8% to 40.2%, a median progression-free survival (PFS) of 3.5 to 6.0 months, and a median OS of 9.2 to 13.0 months (11, 31) . The combination of paclitaxel and oxaliplatin also had enhanced anticancer activity in a gastric cancer cell line (17) .
In order to explore the value of regimens without docetaxel and cisplatin, the POFL regimen was developed and first utilized by Lin et al (18) as first-line treatment for patients with AGC. In a phase II study with 21 patients, they reported an overall response rate of 57.1%, with 19.0% CR and 38.1% PR. The median survival was 11.6 months. The other retrospective study with 127 patients demonstrated that the POFL regimen may be effective in patients with AGC, with an overall response rate of 63.8%, a median PFS of 7.1 months, and a median OS of 11.7 months (32). In our study, combination chemotherapy with POFL in patients with AGC achieved a high rate of overall objective response of 56.3% (95% CI, 47.5%-64.9%). The results are quite similar to those of the study by Lin et al (18) . Our study also showed that patients with well-differentiated histology, gastroesophageal junction disease, and ≤2 metastases benefited from POFL. There was a significant difference in the response rates between patients with ≤2 metastases and those with ≥3 metastases (p = 0.001). The median TTP was 6.7 months (95% CI, 5.8-7.6 months) and the median OS 12.6 months (95% CI, 11.3-13.9 months), calculated from the start of therapy.
The most common toxicities associated with combination chemotherapy with paclitaxel and oxalipltin were myelosuppression and cumulative peripheral neuropathy. Guo et al (32) found that grade 3 and 4 leukopenia occurred in 51 (40.2%) patients. Grade 3 and 4 thrombocytopenia occurred in 3 (2.4%) patients. Grade 3 and 4 peripheral neurotoxicity occurred in 5 (3.9%) patients. In our study, grade 3 and 4 leukopenia occurred in 52 (37.7%) patients. Grade 3 and 4 anemia occurred in 24 (17.4%) patients. Grade 3 and 4 thrombocytopenia occurred in 16 (11.6%) patients. Grade 3 and 4 peripheral neurotoxicity occurred in 23 (16.7%) patients. No patients discontinued the treatment protocol due to peripheral neurotoxicity and there were no treatment-related deaths. All patients with neutropenia recovered 3-4 weeks later on their own or after administration of G-CSF. The toxicity was considered tolerable by the patients.
The prognostic factors including age, disease status, number of metastases and histological differentiation for OS and TTP were identified in the multivariate analysis in patients with AGC, and metastatic site only predicted TTP in multivariate analysis. Metastatic sites including the ovary, peritoneum and lymph nodes were associated with longer TTP than liver, lung and other metastatic sites (bone, pancreas). It may be of clinical importance to consider these factors because they provide us with the keys for future improvements.
In conclusion, combination chemotherapy with POFL is an effective regimen with tolerable toxicity in Chinese patients with AGC. It may provide an alternative option for preoperative treatment in patients with gastric cancer. However, we had a relatively small sample size in this study, and further, larger-size randomized controlled trials need to be conducted to assess its efficacy and determine the optimal paclitaxel dose. 
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